Retatrutide for sale: where to buy retatrutide, and what's legal

If you searched for retatrutide for sale, here is the honest answer to where to buy retatrutide: nowhere, legally. Retatrutide is not approved by the FDA or any other regulator. Lilly, the company developing it, says Anyone purporting to sell retatrutide to consumers is breaking the law. [Lilly, Oct 28, 2026] As of Nov 12, 2026, the only legal ways to get it are a clinical trial or Lilly's expanded access program.

This guide explains what the online listings are and what tests of them found. It then covers how the two legal routes work and which approved medicines you can buy today with a prescription. It doesn't name, rank or link to any seller. For background on the drug itself, start with what is retatrutide.

Is retatrutide for sale anywhere legally?

No. Lilly's position is that retatrutide cannot be legally sold or marketed for human use [Lilly, Oct 28, 2026]. That covers the three places people usually look.

• Pharmacies. A pharmacy can only dispense approved drugs, and retatrutide hasn't been approved [Lilly, Oct 2026]. Lilly hasn't even filed for approval yet [Lilly, Sep 29, 2026].
• Telehealth clinics and compounding pharmacies. The FDA is blunt: Retatrutide and cagrilintide cannot be used in compounding under federal law. [FDA, Oct 1, 2026] So an offer of "retatrutide compounded for you" is not a legal product. The FDA says it has warned telehealth companies for marketing retatrutide, ingredient distributors for selling it to compounders, and outsourcing facilities for repackaging it [FDA, Oct 1, 2026].
• Online "research" sellers. These are most of what a search turns up. The next section explains why that label doesn't make a sale legal.

What are the "retatrutide for sale" listings online?

Most listings sell small vials of powder. The labels say "research use only" or "not for human consumption." Product names often play on nicknames such as "GLP-3," "Reta" or "R-10" [FDA warning letters, Nov 12, 2026] [Victoria Health, Jun 19, 2026]. The FDA's view of that label is direct:

FDA has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled "for research purposes" or "not for human consumption." These products have been sold directly to consumers for human use with dosing instructions. The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health.

That's from the FDA's GLP-1 page [FDA, Oct 1, 2026]. In other words, "retatrutide for research purposes" is not a loophole. If a website sells the vial to you for use in people, the FDA treats it as an unapproved drug.

How many FDA warning letters name retatrutide?

On Nov 12, 2026, a search of FDA's warning-letter database returned 21 letters that name retatrutide [FDA warning letters, Nov 12, 2026]. We opened each one. They fall into six batches.

Source: FDA warning-letter database, regulator [FDA warning letters, Nov 12, 2026]. Thirteen of the 21 letters went to online sellers. Letters are posted online with a delay, so later ones may exist.

Why is Lilly suing sellers?

On Aug 12, 2026, Lilly said it had filed six new lawsuits against U.S. sellers. Its targets included compounding pharmacies, medical spas and online sellers that falsely claim their drugs are for "research-use only" [Lilly, Aug 12, 2026]. Lilly also said it had referred more than 200 people and companies to regulators and law enforcement. It had reported more than 14,000 websites, ads, posts and listings in over 100 countries [Lilly, Aug 12, 2026]. These are company figures. We found no court ruling in the suits as of Nov 12, 2026.

What did tests of products sold as retatrutide find?

The few tests made public point the same way: you can't tell what's in the vial.

• Australia's regulator (TGA), Sep 14, 2026. A person who thought they were using retatrutide had uncontrollable vomiting that tore their esophagus, and needed hospital care. The TGA's lab found no retatrutide in the product. Instead it held undeclared semaglutide at about 8 times the level found in approved semaglutide products [TGA, Sep 14, 2026].
• Victoria's health department (Australia), Jun 19, 2026. It reported six cases of acute liver injury since January 2026 in people who used products labeled retatrutide. It said the harm was possibly associated with a contaminant and that all such products are at risk [Victoria Health, Jun 19, 2026].
• CBS News, Oct 21, 2026 (news report). A University of Iowa scientist tested three samples. Two bought online matched a basic retatrutide standard, which CBS said isn't the same as the drug being studied in Eli Lilly's clinical trials. A third, bought at a corner store, didn't appear to contain a peptide at all. It held a chemical the scientist called a filler, and further testing found 13 colonies of bacteria [CBS News, Oct 21, 2026].

No peer-reviewed study has tested the purity of retatrutide sold online. A PubMed search on Nov 12, 2026 found only case reports of people who became ill, and no product testing [PubMed, Nov 12, 2026]. The closest study looked at semaglutide from illegal online pharmacies. Pens ordered from those sites never arrived, which the authors called scams. The vials that did arrive held 28.56% to 38.69% more drug than labeled, and endotoxin, a bacterial toxin, turned up in every sample [JMIR, 2024].

Harm reports are growing too. CBS reported in October that FDA adverse-event files describe two deaths linked to products claiming to be retatrutide. The reports alone don't prove the products caused the deaths, and the FDA wouldn't say whether it had checked them [CBS News, Oct 13, 2026]. The same report says US poison centers logged 862 retatrutide exposures in the three months ending in September 2026. In the first three months of the year, they logged 249 [CBS News, Oct 13, 2026].

What can a seller's lab report show?

Many sellers post a certificate of analysis, often called a COA. At best, it says that one sample, tested once, contained a peptide of the expected size at a stated purity. It doesn't show that your vial came from the same batch. It doesn't show that the vial is sterile, free of bacterial toxins, or the same molecule Lilly makes. And it says nothing about how the powder held up in shipping and storage.

The CBS test shows the gap. Two samples matched a basic standard and still weren't the trial drug [CBS News, Oct 21, 2026]. Lilly's response to CBS put it this way: A single test is a snapshot, not a guarantee that the dose will be sterile or stable in two weeks, let alone that the next vial will be safe. [CBS News, Oct 21, 2026] Lilly also warns that illicit products may contain too much or too little active ingredient, or the wrong ingredient entirely [Lilly, Oct 2026].

Is it legal to buy retatrutide?

We can't give legal advice, and the answer can depend on your state and country. Here is what the sources show.

Federal law clearly bars selling it. The drug law makes it a prohibited act to ship an unapproved new drug across state lines [21 U.S.C. 331], and the FDA's letters rest on that rule [FDA warning letters, Nov 12, 2026]. The same law also lists The receipt in interstate commerce of a misbranded drug as a prohibited act [21 U.S.C. 331]. So buyers are not clearly outside it. In practice, every FDA action and Lilly lawsuit we found targets sellers, clinics, pharmacies or suppliers [FDA warning letters, Nov 12, 2026] [Lilly, Aug 12, 2026]. We found no reported case of a US consumer charged for buying retatrutide as of Nov 12, 2026. That is not the same as saying buying it is legal or safe.

Ordering it from abroad doesn't help. The FDA says that In most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use [FDA, Aug 18, 2025]. Retatrutide isn't approved in any country, and the FDA may refuse a parcel that appears to pose a serious health risk [FDA, Aug 18, 2025].

Where to buy retatrutide legally: the two routes

Neither route is a purchase. Both supply Lilly's own drug under medical supervision, though a trial volunteer may get a comparison drug or placebo instead.

Route 1: a clinical trial

On Nov 12, 2026, ClinicalTrials.gov listed 33 retatrutide studies. Of these, 21 were completed, 9 were active but no longer recruiting, 2 were recruiting and 1 was the expanded access program [ClinicalTrials.gov, Nov 12, 2026]. Most big trials are full.

The recruiting Lilly trial is SYNERGY-Outcomes (NCT07165028), a phase 3 study in fatty liver disease (MASLD) aiming to enroll about 4,500 adults. It tests retatrutide and tirzepatide, each against placebo, so a volunteer may not get retatrutide at all. It had 137 recruiting sites in the US. It's for people with liver fat and liver stiffness in set ranges, measured at screening, not a weight-loss trial [ClinicalTrials.gov, NCT07165028]. The other recruiting record lists a non-Lilly sponsor and a single site in China. We could not verify it, so we don't count it as a route.

How to check if you might qualify:

1. Search ClinicalTrials.gov with "retatrutide" in the treatment field, filter for "Recruiting" and "Not yet recruiting," and add your location [ClinicalTrials.gov, Nov 12, 2026].
2. Read the inclusion and exclusion list on the record, then contact the site listed.
3. Or call Lilly's trial line, 1-877-285-4559, or text YES to 317-854-5591, on weekdays [Lilly Trials, Nov 2026].

Lilly says that in most of its trials the study drug and visits come at no cost, but this is not the case for all trials [Lilly Trials, Nov 2026]. Some trials pay or reimburse volunteers, and you hear about costs during informed consent, before you agree to take part [Lilly Trials, Nov 2026].

Route 2: Lilly's expanded access program

Expanded access lets a seriously ill patient use an unapproved drug outside a trial. Lilly posted its single-patient expanded access record in June 2026 (NCT07629401) [ClinicalTrials.gov, NCT07629401]. Its main criteria:

• Adults only.
• Obesity that hasn't responded to treatment: a BMI still at 35 or higher after taking and tolerating the top dose available of a weight medicine.
• Two or more serious or life-threatening complications of obesity, already being treated.
• No way into a retatrutide trial, because of eligibility rules or distance.
• All standard options, including bariatric surgery, discussed with the patient.

You can't apply yourself. The record says requests come from the treating doctor, who contacts the Lilly Answers Center at 1-800-545-5979. It adds that availability depends on geography, product supply, and detailed individual eligibility assessment [ClinicalTrials.gov, NCT07629401]. Lilly provides the drug at no cost. The doctor acts as the sponsor, which means getting ethics board approval and applying to the FDA [Lilly Medical, Aug 26, 2026]. The FDA notes that the doctor, the ethics board and the company all have to agree. It adds that some costs may not be covered by insurance [FDA, Oct 29, 2026].

What can you buy today instead?

Several medicines are FDA approved for long-term weight management and can be bought legally with a prescription. Zepbound and Wegovy are retatrutide's closest approved relatives: tirzepatide acts on two of its three receptors, and semaglutide on one. Both drug makers sell them directly to self-paying patients. Here are their own prices, checked Nov 12, 2026.

Prices can change. New Wegovy injection patients pay $199 a month for their first two fills of the two lowest strengths, through Dec 31, 2026 [NovoCare, Nov 12, 2026]. Lilly has also cut two Foundayo strengths until the same date [Lilly, Foundayo savings, Nov 12, 2026]. Foundayo, a daily pill from Lilly, was approved on Apr 1, 2026 [Drugs@FDA, NDA 220934]. Every offer needs a prescription for an approved use consistent with FDA-approved product labeling, in Lilly's words [Lilly, Zepbound savings, Nov 12, 2026]. The federal TrumpRx site lists Zepbound at $299, Wegovy tablets at $149 and Wegovy pens at $199 a month [TrumpRx, Nov 12, 2026].

Older approved options include Saxenda (liraglutide) [DailyMed, Saxenda], Qsymia (phentermine and topiramate) [DailyMed, Qsymia], Contrave (naltrexone and bupropion) [DailyMed, Contrave] and Xenical (orlistat) [DailyMed, Xenical]. Imcivree (setmelanotide) is approved only for certain rare genetic or hypothalamic forms of obesity [DailyMed, Imcivree]. We couldn't confirm a manufacturer self-pay price for these on Nov 12, 2026, so ask your pharmacy. A clinician can tell you which, if any, suits you. The retatrutide cost guide covers insurance and Medicare, and retatrutide vs tirzepatide compares the trial results.

When could retatrutide be at pharmacies?

Not before the FDA approves it, and that can't happen until Lilly files. Lilly's plan: Lilly plans to submit a Biologics License Application (BLA) in Q1 2027 to the U.S. Food and Drug Administration. [Lilly, Sep 29, 2026] Even the filing type is disputed. The FDA has ruled that retatrutide is a drug, not a biologic. Lilly is appealing, and told the court it needs to know which application pathway (biological product or drug) to pursue [7th Cir. filing, Oct 8, 2026]. We found no ruling as of Nov 12, 2026.

A filing starts an FDA review; it is not an approval. The retatrutide FDA approval timeline sets out the review clocks and what could change them. Until an approval, no pharmacy in the USA or elsewhere can legally stock it.

Red flags that a retatrutide listing is illegal or a scam

These are reasons for caution, not a checklist for picking a seller. A listing that shows none of them is still illegal.

• No prescription needed. The FDA warns that an online pharmacy that Does not require a doctor's prescription may be unsafe [FDA BeSafeRx, Sep 21, 2020].
• A "research" label with dosing or mixing directions. That combination is exactly what the FDA describes in its warnings [FDA, Oct 1, 2026].
• Claims that it's approved, "pharmaceutical grade" or "the same as Lilly's." It isn't approved anywhere [Lilly, Oct 28, 2026], and Lilly hasn't announced a brand name [Lilly, Oct 2026].
• "Compounded retatrutide" from a clinic or telehealth service. It can't legally be compounded [FDA, Oct 1, 2026].
• Payment and pricing problems. The FDA's warning signs include prices that seem too good to be true and charges for products you never ordered [FDA BeSafeRx, Sep 21, 2020]. Lilly has asked credit card companies and payment processors to stop serving retatrutide sellers [Lilly, Aug 12, 2026]. We found no regulator list of risky payment methods.
• A lab report offered as proof of safety. As explained above, one test can't vouch for your vial.

If you already have a product sold as retatrutide, Victoria's health department advises people not to use it and to dispose of it safely [Victoria Health, Jun 19, 2026]. The note below covers what to do if you have injected it.